Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis
In: Oncogene, Jg. 30 (2011-04-25), S. 4208-4218
Online
unknown
Zugriff:
Mammalian Ste20-like kinase-1 (MST1) kinase mediates H₂O₂-induced cell death by anticancer drugs such as cisplatin in a p53-dependent manner. However, the mechanism underlying MST1 activation by H₂O₂ remains unknown. Here we show that peroxiredoxin-I (PRX-I) is an essential intermediate in H₂O₂-induced MST1 activation and cisplatin-induced cell death through p53. Cell stimulation with H₂O₂ resulted in PRX-I oxidation to form homo-oligomers and interaction with MST1, leading to MST1 autophosphorylation and augmentation of kinase activity. In addition, RNA interference knockdown experiments indicated that endogenous PRX-I is required for H₂O₂-induced MST1 activation. Live-cell imaging showed H₂O₂ generation by cisplatin treatment, which likewise caused PRX-I oligomer formation, MST1 activation and cell death. Cisplatin-induced PRX-I oligomer formation was not observed in embryonic fibroblasts obtained from p53-knockout mice, confirming the importance of p53. Indeed, ectopic expression of p53 induced PRX-I oligomer formation and cell death, both of which were cancelled by the antioxidant NAC. Moreover, we succeeded in reconstituting H₂O₂-induced MST1 activation in vitro, using purified PRX-I and MST1 proteins. Collectively, our results show a novel PRX-I function to cause cell death in response to high levels of oxidative stress by activating MST1, which underlies the p53-dependent cytotoxicity caused by anticancer agents.
Titel: |
Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis
|
---|---|
Autor/in / Beteiligte Person: | Uesugi, K ; Miki, Hiroaki ; Morinaka, Akifumi ; Funato, Yosuke |
Link: | |
Zeitschrift: | Oncogene, Jg. 30 (2011-04-25), S. 4208-4218 |
Veröffentlichung: | Springer Science and Business Media LLC, 2011 |
Medientyp: | unknown |
ISSN: | 1476-5594 (print) ; 0950-9232 (print) |
DOI: | 10.1038/onc.2011.139 |
Schlagwort: |
|
Sonstiges: |
|